All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type cancer type (metastatic) cancer type (recurrent) cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 EGFR mutant Gender, female Gender, male metastasis (bone) metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PD-L1 < 1% PD-L1 > 1% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) PDL1 (TPS >50%) smoker (current or former) smoker (Current) smoker (Former) smoker (never) stage III (locally advanced) stage IV (metastatic) Teff high Teff low
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), immune chekpoint inhibitors vs. chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 026 (PDL1>1%), 2016 1.07 [0.86; 1.33]
CheckMate 026 (PDL1>5%), 2016 1.02 [0.80; 1.30]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.78 [0.60; 1.02]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.79 [0.65; 0.96]
CheckMate 9LA, 2021 0.69 [0.55; 0.87]
EMPOWER lung1 (all population), 2021 0.68 [0.53; 0.87]
EMPOWER lung1 (PDL1>50%), 2021 0.57 [0.42; 0.77]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.83 [0.65; 1.06]
IMpower-110 (TC2/3 or IC2/3), 2020 0.72 [0.52; 0.99]
IMpower-110 (TC3 or IC3), 2020 0.59 [0.40; 0.88]
IMpower-130 (WT), 2019 0.79 [0.64; 0.98]
IMpower-131 (ACnP), 2020 0.88 [0.73; 1.06]
KEYNOTE-021, 2016 0.90 [0.42; 1.92]
KEYNOTE-024 (PDL1>50%), 2016 0.60 [0.41; 0.88]
KEYNOTE-042 (PDL1>1%), 2019 0.81 [0.71; 0.93]
KEYNOTE-042 (PDL1>20%), 2019 0.77 [0.64; 0.92]
KEYNOTE-042 (PDL1>50%), 2019 0.69 [0.56; 0.85]
KEYNOTE-189, 2018 0.49 [0.38; 0.64]
KEYNOTE-407, 2018 0.64 [0.49; 0.84]
MYSTIC (D ; all population), 2020 0.96 [0.81; 1.13]
MYSTIC (D ; PDL1>25%), 2020 0.76 [0.56; 1.03]
MYSTIC (DT ; all population), 2020 0.94 [0.80; 1.11]
MYSTIC (DT ; PDL1>25%), 2020 0.85 [0.61; 1.18]
ORIENT-11, 2020 0.61 [0.40; 0.93]
0.77 [0.71 ; 0.83 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 026 (PDL1>5%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, EMPOWER lung1 (PDL1>50%), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, IMpower-130 (WT), 2019, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020, ORIENT-11, 2020 24 57% 13,392 moderate critical deaths (OS) (extension)detailed results CheckMate 9LA, 2021 0.66 [0.55; 0.80]
IMpower-110 (TC3 or IC3), 2020 0.76 [0.53; 1.08]
KEYNOTE-021, 2016 0.71 [0.45; 1.12]
KEYNOTE-024 (PDL1>50%), 2016 0.62 [0.48; 0.81]
KEYNOTE-042 (PDL1>1%), 2019 0.80 [0.71; 0.90]
KEYNOTE-042 (PDL1>20%), 2019 0.75 [0.64; 0.88]
KEYNOTE-042 (PDL1>50%), 2019 0.98 [0.82; 1.18]
KEYNOTE-189, 2018 0.56 [0.45; 0.70]
0.73 [0.64 ; 0.83 ] CheckMate 9LA, 2021, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018 8 65% 4,659 moderate not evaluable PFS (extension)detailed results CheckMate 9LA, 2021 0.68 [0.57; 0.82]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.72 [0.60; 0.86]
IMpower-110 (TC2/3 or IC2/3), 2020 0.64 [0.50; 0.82]
IMpower-110 (TC3 or IC3), 2020 0.59 [0.43; 0.81]
KEYNOTE-021, 2016 0.54 [0.35; 0.83]
KEYNOTE-024 (PDL1>50%), 2016 0.50 [0.39; 0.65]
KEYNOTE-042 (PDL1>1%), 2019 1.05 [0.93; 1.18]
KEYNOTE-042 (PDL1>20%), 2019 0.95 [0.82; 1.10]
KEYNOTE-042 (PDL1>50%), 2019 0.85 [0.71; 1.01]
KEYNOTE-189, 2018 0.48 [0.40; 0.58]
0.69 [0.57 ; 0.83 ] CheckMate 9LA, 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018 10 89% 5,541 moderate critical progression or deaths (PFS)detailed results CheckMate 026 (PDL1>1%), 2016 1.17 [0.95; 1.44]
CheckMate 026 (PDL1>5%), 2016 1.15 [0.91; 1.45]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.73 [0.56; 0.95]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.82 [0.69; 0.97]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.58 [0.41; 0.82]
CheckMate 9LA, 2021 0.70 [0.57; 0.86]
EMPOWER lung1 (all population), 2021 0.59 [0.49; 0.72]
EMPOWER lung1 (PDL1>50%), 2021 0.54 [0.43; 0.68]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.77 [0.63; 0.94]
IMpower-110 (TC2/3 or IC2/3), 2020 0.67 [0.52; 0.87]
IMpower-110 (TC3 or IC3), 2020 0.63 [0.45; 0.88]
IMpower-130 (WT), 2019 0.64 [0.54; 0.76]
IMpower-131 (ACnP), 2020 0.71 [0.60; 0.85]
KEYNOTE-021, 2016 0.53 [0.31; 0.91]
KEYNOTE-024 (PDL1>50%), 2016 0.50 [0.37; 0.68]
KEYNOTE-042 (PDL1>1%), 2019 1.07 [0.94; 1.21]
KEYNOTE-042 (PDL1>20%), 2019 0.94 [0.80; 1.11]
KEYNOTE-042 (PDL1>50%), 2019 0.81 [0.67; 0.98]
KEYNOTE-189, 2018 0.52 [0.43; 0.63]
KEYNOTE-407, 2018 0.56 [0.45; 0.70]
MYSTIC (D ; PDL1>25%), 2020 0.87 [0.59; 1.29]
MYSTIC (DT ; PDL1>25%), 2020 1.05 [0.72; 1.53]
ORIENT-11, 2020 0.48 [0.36; 0.64]
0.72 [0.64 ; 0.81 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 026 (PDL1>5%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, EMPOWER lung1 (PDL1>50%), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, IMpower-130 (WT), 2019, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; PDL1>25%), 2020, ORIENT-11, 2020 23 83% 12,201 moderate critical DORdetailed results IMpower-130 (WT), 2019 2.41 [1.27; 4.60]
IMpower-131 (ACnP), 2020 2.14 [1.13; 4.04]
2.27 [1.44 ; 3.57 ] IMpower-130 (WT), 2019, IMpower-131 (ACnP), 2020 2 0% 601 moderate not evaluable objective responses (ORR)detailed results CheckMate 026 (PDL1>5%), 2016 0.70 [0.46; 1.06]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 1.31 [0.97; 1.76]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2.26 [1.39; 3.66]
CheckMate 9LA, 2021 1.80 [1.31; 2.48]
EMPOWER lung1 (all population), 2021 2.21 [1.58; 3.10]
EMPOWER lung1 (PDL1>50%), 2021 2.53 [1.32; 4.85]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.89 [0.62; 1.27]
IMpower-110 (TC2/3 or IC2/3), 2020 0.94 [0.59; 1.50]
IMpower-110 (TC3 or IC3), 2020 1.55 [0.86; 2.79]
IMpower-130 (WT), 2019 2.07 [1.48; 2.89]
IMpower-131 (ACnP), 2020 1.42 [1.05; 1.92]
KEYNOTE-021, 2016 3.06 [1.45; 6.45]
KEYNOTE-024 (PDL1>50%), 2016 2.11 [1.31; 3.39]
KEYNOTE-042 (PDL1>1%), 2019 1.04 [0.81; 1.33]
KEYNOTE-042 (PDL1>20%), 2019 1.24 [0.92; 1.66]
KEYNOTE-042 (PDL1>50%), 2019 1.39 [0.99; 1.94]
KEYNOTE-189, 2018 3.88 [2.61; 5.79]
KEYNOTE-407, 2018 2.20 [1.57; 3.09]
MYSTIC (D ; PDL1>25%), 2020 0.91 [0.58; 1.43]
MYSTIC (DT ; PDL1>25%), 2020 0.87 [0.55; 1.37]
ORIENT-11, 2020 2.54 [1.63; 3.97]
1.55 [1.29 ; 1.87 ] CheckMate 026 (PDL1>5%), 2016, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, EMPOWER lung1 (PDL1>50%), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, IMpower-130 (WT), 2019, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; PDL1>25%), 2020, ORIENT-11, 2020 21 80% 11,291 moderate low objective responses (ORR) (extension)detailed results IMpower-110 (TC3 or IC3), 2020 1.68 [0.94; 3.01]
KEYNOTE-021, 2016 2.80 [1.34; 5.83]
KEYNOTE-024 (PDL1>50%), 2016 1.89 [1.19; 3.02]
KEYNOTE-042 (PDL1>1%), 2019 1.03 [0.81; 1.32]
KEYNOTE-042 (PDL1>20%), 2019 1.21 [0.90; 1.62]
KEYNOTE-042 (PDL1>50%), 2019 1.35 [0.96; 1.88]
KEYNOTE-189, 2018 3.84 [2.58; 5.70]
1.72 [1.20 ; 2.47 ] IMpower-110 (TC3 or IC3), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018 7 84% 3,940 moderate not evaluable AE (any grade)detailed results EMPOWER lung1 (all population), 2021 0.18 [0.12; 0.27]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.52 [0.27; 1.01]
IMpower-131 (ACnP), 2020 5.12 [1.11; 23.56]
KEYNOTE-189, 2018 4.04 [0.36; 44.82]
KEYNOTE-407, 2018 1.20 [0.36; 3.96]
MYSTIC (D ; all population), 2020 0.59 [0.31; 1.13]
MYSTIC (D ; PDL1>25%), 2020 0.42 [0.14; 1.22]
MYSTIC (DT ; all population), 2020 0.51 [0.27; 0.96]
MYSTIC (DT ; PDL1>25%), 2020 0.43 [0.15; 1.24]
ORIENT-11, 2020 1.02 [0.03; 30.46]
0.61 [0.35 ; 1.09 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020, ORIENT-11, 2020 10 74% 5,550 moderate critical AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.19 [0.13; 0.29]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.39 [0.27; 0.55]
IMpower-131 (ACnP), 2020 1.37 [0.98; 1.90]
KEYNOTE-189, 2018 1.03 [0.73; 1.45]
KEYNOTE-407, 2018 0.99 [0.70; 1.39]
MYSTIC (D ; all population), 2020 0.81 [0.60; 1.10]
MYSTIC (D ; PDL1>25%), 2020 0.91 [0.58; 1.41]
MYSTIC (DT ; all population), 2020 1.02 [0.76; 1.37]
MYSTIC (DT ; PDL1>25%), 2020 0.86 [0.56; 1.35]
ORIENT-11, 2020 1.13 [0.74; 1.73]
0.78 [0.55 ; 1.09 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020, ORIENT-11, 2020 10 89% 5,550 moderate low AE leading to death (grade 5)detailed results EMPOWER lung1 (all population), 2021 1.24 [0.46; 3.38]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.39; 2.15]
IMpower-131 (ACnP), 2020 2.59 [1.36; 4.92]
KEYNOTE-189, 2018 1.13 [0.56; 2.28]
KEYNOTE-407, 2018 1.31 [0.69; 2.49]
MYSTIC (D ; all population), 2020 0.82 [0.38; 1.75]
MYSTIC (D ; PDL1>25%), 2020 0.75 [0.20; 2.86]
MYSTIC (DT ; all population), 2020 2.19 [1.17; 4.11]
MYSTIC (DT ; PDL1>25%), 2020 3.45 [1.24; 9.59]
ORIENT-11, 2020 0.31 [0.11; 0.90]
1.28 [0.87 ; 1.89 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020, ORIENT-11, 2020 10 56% 5,550 moderate low AE leading to treatment discontinuation (any grade)detailed results EMPOWER lung1 (all population), 2021 1.62 [0.82; 3.21]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.34 [0.19; 0.61]
IMpower-131 (ACnP), 2020 2.09 [1.45; 3.02]
KEYNOTE-189, 2018 2.19 [1.31; 3.65]
KEYNOTE-407, 2018 2.28 [1.45; 3.61]
MYSTIC (D ; all population), 2020 0.72 [0.47; 1.12]
MYSTIC (D ; PDL1>25%), 2020 0.75 [0.38; 1.46]
MYSTIC (DT ; all population), 2020 1.43 [0.97; 2.10]
MYSTIC (DT ; PDL1>25%), 2020 1.63 [0.91; 2.93]
ORIENT-11, 2020 0.70 [0.31; 1.55]
1.21 [0.82 ; 1.77 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020, ORIENT-11, 2020 10 82% 5,550 moderate low AE leading to treatment discontinuation (grade 3-4)detailed results KEYNOTE-189, 2018 2.04 [1.16; 3.59]
KEYNOTE-407, 2018 2.09 [1.28; 3.39]
MYSTIC (D ; all population), 2020 1.10 [0.64; 1.89]
MYSTIC (DT ; all population), 2020 2.14 [1.32; 3.47]
ORIENT-11, 2020 0.64 [0.26; 1.56]
1.58 [1.08 ; 2.31 ] KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 5 56% 3,006 low not evaluable SAE (any grade)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.99 [0.68; 1.44]
IMpower-131 (ACnP), 2020 2.28 [1.66; 3.14]
MYSTIC (D ; PDL1>25%), 2020 1.22 [0.77; 1.94]
MYSTIC (DT ; PDL1>25%), 2020 1.93 [1.22; 3.04]
1.53 [1.01 ; 2.31 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; PDL1>25%), 2020 4 77% 1,847 moderate not evaluable STRAE (any grade)detailed results CheckMate 026 (PDL1>1%), 2016 0.93 [0.60; 1.46]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.75 [1.00; 3.09]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 1.96 [1.36; 2.83]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2.67 [1.51; 4.74]
CheckMate 9LA, 2021 1.94 [1.36; 2.76]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.50 [0.29; 0.85]
IMpower-131 (ACnP), 2020 2.27 [1.46; 3.51]
KEYNOTE-021, 2016 3.47 [1.25; 9.62]
KEYNOTE-024 (PDL1>50%), 2016 1.05 [0.60; 1.82]
MYSTIC (D ; all population), 2020 0.56 [0.35; 0.90]
MYSTIC (D ; PDL1>25%), 2020 0.38 [0.18; 0.77]
MYSTIC (DT ; all population), 2020 1.52 [1.03; 2.24]
MYSTIC (DT ; PDL1>25%), 2020 1.05 [0.59; 1.87]
1.26 [0.91 ; 1.75 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 13 82% 6,380 moderate low STRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.82 [0.50; 1.33]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 2.05 [1.12; 3.76]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 1.98 [1.32; 2.98]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2.19 [1.14; 4.20]
CheckMate 9LA, 2021 1.95 [1.33; 2.84]
KEYNOTE-021, 2016 5.56 [1.49; 20.67]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.55; 1.72]
MYSTIC (D ; all population), 2020 0.48 [0.28; 0.84]
MYSTIC (DT ; all population), 2020 1.43 [0.92; 2.21]
1.43 [0.99 ; 2.06 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 9 76% 4,533 moderate not evaluable TRAE (any grade)detailed results CheckMate 026 (PDL1>1%), 2016 0.20 [0.12; 0.34]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 3.42 [1.76; 6.65]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.66 [0.46; 0.94]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.28 [0.71; 2.30]
CheckMate 9LA, 2021 1.55 [0.94; 2.55]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.27 [0.18; 0.40]
IMpower-131 (ACnP), 2020 1.80 [0.98; 3.28]
KEYNOTE-021, 2016 0.95 [0.29; 3.12]
KEYNOTE-024 (PDL1>50%), 2016 0.31 [0.16; 0.58]
KEYNOTE-042 (PDL1>1%), 2019 0.19 [0.14; 0.26]
MYSTIC (D ; all population), 2020 0.24 [0.17; 0.34]
MYSTIC (D ; PDL1>25%), 2020 0.21 [0.12; 0.38]
MYSTIC (DT ; all population), 2020 0.31 [0.22; 0.44]
MYSTIC (DT ; PDL1>25%), 2020 0.17 [0.09; 0.30]
0.49 [0.31 ; 0.78 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 14 92% 7,631 moderate low TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.21 [0.14; 0.31]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 2.35 [1.53; 3.60]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.96 [0.72; 1.29]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.02 [0.64; 1.65]
CheckMate 9LA, 2021 1.44 [1.06; 1.94]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.19 [0.12; 0.29]
IMpower-131 (ACnP), 2020 1.57 [1.14; 2.15]
KEYNOTE-021, 2016 2.04 [0.92; 4.52]
KEYNOTE-024 (PDL1>50%), 2016 0.32 [0.20; 0.51]
KEYNOTE-042 (PDL1>1%), 2019 0.30 [0.23; 0.39]
MYSTIC (D ; all population), 2020 0.34 [0.24; 0.49]
MYSTIC (D ; PDL1>25%), 2020 0.36 [0.22; 0.61]
MYSTIC (DT ; all population), 2020 0.55 [0.39; 0.77]
MYSTIC (DT ; PDL1>25%), 2020 0.36 [0.22; 0.60]
0.60 [0.39 ; 0.94 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 14 95% 7,631 moderate low TRAE leading to death (grade 5)detailed results CheckMate 227 (NC vs C ; PDL1<1%), 2018 4.33 [0.48; 39.16]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.99 [0.28; 3.45]
CheckMate 9LA, 2021 1.14 [0.38; 3.43]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.02; 13.73]
IMpower-131 (ACnP), 2020 1.34 [0.30; 6.02]
KEYNOTE-021, 2016 0.52 [0.05; 5.86]
KEYNOTE-024 (PDL1>50%), 2016 0.32 [0.03; 3.11]
KEYNOTE-042 (PDL1>1%), 2019 0.90 [0.42; 1.92]
KEYNOTE-407, 2018 1.70 [0.61; 4.75]
MYSTIC (D ; all population), 2020 0.63 [0.11; 3.82]
MYSTIC (D ; PDL1>25%), 2020 0.95 [0.06; 15.32]
MYSTIC (DT ; all population), 2020 1.91 [0.47; 7.71]
MYSTIC (DT ; PDL1>25%), 2020 0.94 [0.06; 15.13]
1.10 [0.74 ; 1.64 ] CheckMate 227 (NC vs C ; PDL1<1%), 2018, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 9LA, 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 13 0% 7,365 moderate low TRAE leading to discontinuation (any grade)detailed results CheckMate 026 (PDL1>1%), 2016 0.70 [0.41; 1.20]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.89 [0.48; 1.63]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 3.13 [1.95; 5.03]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 3.49 [1.78; 6.83]
CheckMate 9LA, 2021 3.18 [1.94; 5.19]
KEYNOTE-021, 2016 0.76 [0.25; 2.35]
KEYNOTE-024 (PDL1>50%), 2016 0.64 [0.29; 1.44]
KEYNOTE-042 (PDL1>1%), 2019 0.95 [0.64; 1.39]
MYSTIC (D ; all population), 2020 0.55 [0.31; 0.99]
MYSTIC (D ; PDL1>25%), 2020 0.47 [0.21; 1.04]
MYSTIC (DT ; all population), 2020 1.47 [0.92; 2.35]
MYSTIC (DT ; PDL1>25%), 2020 1.04 [0.54; 2.03]
1.16 [0.78 ; 1.73 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 12 82% 6,414 moderate low TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.24 [0.64; 2.40]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.80 [0.38; 1.70]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 5.13 [2.63; 10.00]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2.90 [1.32; 6.37]
CheckMate 9LA, 2021 3.48 [2.00; 6.05]
KEYNOTE-021, 2016 4.44 [0.48; 40.91]
KEYNOTE-024 (PDL1>50%), 2016 0.86 [0.32; 2.29]
KEYNOTE-042 (PDL1>1%), 2019 1.09 [0.71; 1.66]
MYSTIC (D ; all population), 2020 1.28 [0.60; 2.75]
MYSTIC (DT ; all population), 2020 2.95 [1.51; 5.78]
1.87 [1.21 ; 2.88 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 10 73% 5,784 moderate low Acute kidney injury TRAE (grade 3-4)detailed results KEYNOTE-021, 2016 4.32 [0.19; 97.73]
4.32 [0.19 ; 97.73 ] KEYNOTE-021, 2016 1 0% 121 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 7.88 [0.41; 149.53]
IMpower-131 (ACnP), 2020 2.00 [0.07; 59.91]
KEYNOTE-042 (PDL1>1%), 2019 3.88 [0.17; 86.15]
KEYNOTE-189, 2018 0.50 [0.03; 8.00]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
MYSTIC (DT ; all population), 2020 5.73 [0.29; 114.82]
2.57 [0.73 ; 9.04 ] CheckMate 9LA, 2021, IMpower-131 (ACnP), 2020, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 0% 4,677 moderate not evaluable Alopecia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-042 (PDL1>1%), 2019 0.07 [0.00; 1.21]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.48 [0.11 ; 2.13 ] CheckMate 026 (PDL1>1%), 2016, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 0% 4,014 moderate serious Anaemia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.02 [0.00; 0.13]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.34 [0.75; 2.38]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.11 [0.04; 0.28]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.26 [0.07; 0.92]
CheckMate 9LA, 2021 0.37 [0.22; 0.63]
IMpower-131 (ACnP), 2020 1.09 [0.76; 1.58]
KEYNOTE-021, 2016 0.79 [0.27; 2.29]
KEYNOTE-024 (PDL1>50%), 2016 0.08 [0.02; 0.28]
KEYNOTE-042 (PDL1>1%), 2019 0.04 [0.02; 0.12]
MYSTIC (D ; all population), 2020 0.01 [0.00; 0.19]
MYSTIC (DT ; all population), 2020 0.01 [0.00; 0.19]
0.18 [0.08 ; 0.41 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 11 90% 6,452 moderate critical Arthralgia TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
0.98 [0.06 ; 15.75 ] IMpower-131 (ACnP), 2020, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,919 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.12 [0.01; 2.31]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.06 [0.07; 17.15]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 1.24 [0.33; 4.65]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.18 [0.23; 5.95]
CheckMate 9LA, 2021 0.36 [0.09; 1.37]
IMpower-131 (ACnP), 2020 0.77 [0.28; 2.10]
KEYNOTE-042 (PDL1>1%), 2019 0.29 [0.08; 1.05]
MYSTIC (D ; all population), 2020 0.12 [0.01; 0.94]
MYSTIC (DT ; all population), 2020 0.06 [0.00; 1.01]
0.49 [0.27 ; 0.89 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, IMpower-131 (ACnP), 2020, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 9 18% 6,027 moderate not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-024 (PDL1>50%), 2016 0.49 [0.02; 14.58]
1.00 [0.13 ; 7.77 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016 3 0% 955 moderate not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 9.87 [0.54; 181.39]
EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
IMpower-131 (ACnP), 2020 8.08 [0.43; 153.53]
KEYNOTE-024 (PDL1>50%), 2016 3.93 [0.18; 87.97]
KEYNOTE-042 (PDL1>1%), 2019 3.89 [0.43; 34.87]
KEYNOTE-189, 2018 3.01 [0.15; 60.33]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
MYSTIC (DT ; all population), 2020 13.52 [0.76; 239.13]
4.54 [1.70 ; 12.15 ] CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 9 0% 6,227 moderate not evaluable Constipation TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.26 [0.01; 5.89]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.99 [0.02; 50.01]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.59 [0.02; 17.65]
CheckMate 9LA, 2021 0.97 [0.02; 49.27]
IMpower-131 (ACnP), 2020 0.50 [0.02; 14.93]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
MYSTIC (D ; all population), 2020 0.48 [0.02; 14.24]
MYSTIC (DT ; all population), 2020 0.47 [0.02; 14.16]
0.64 [0.21 ; 1.90 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 11 0% 6,452 moderate critical Decreased appetite TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.24 [0.03; 2.19]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.43 [0.32; 6.48]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.99 [0.25; 3.99]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.29 [0.03; 2.62]
CheckMate 9LA, 2021 0.97 [0.24; 3.93]
IMpower-131 (ACnP), 2020 3.41 [0.93; 12.49]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-024 (PDL1>50%), 2016 0.12 [0.01; 2.27]
KEYNOTE-042 (PDL1>1%), 2019 0.53 [0.18; 1.60]
MYSTIC (D ; all population), 2020 0.24 [0.03; 2.13]
MYSTIC (DT ; all population), 2020 0.95 [0.24; 3.82]
0.82 [0.49 ; 1.37 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 11 8% 6,452 moderate low Diabetes TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 6.05 [0.30; 121.16]
KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-189, 2018 1.00 [0.03; 29.86]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 1.90 [0.06; 56.82]
2.04 [0.45 ; 9.27 ] IMpower-131 (ACnP), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 5 0% 3,023 moderate serious Diarrhoea TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.59 [0.14; 2.48]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.06 [0.15; 7.64]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 3.00 [0.60; 14.96]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.78 [0.29; 10.84]
CheckMate 9LA, 2021 7.06 [1.59; 31.30]
EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
IMpower-131 (ACnP), 2020 1.44 [0.54; 3.83]
KEYNOTE-021, 2016 0.52 [0.02; 15.84]
KEYNOTE-024 (PDL1>50%), 2016 3.00 [0.60; 15.11]
KEYNOTE-042 (PDL1>1%), 2019 4.87 [0.57; 41.77]
MYSTIC (D ; all population), 2020 0.95 [0.13; 6.81]
MYSTIC (DT ; all population), 2020 4.35 [0.93; 20.28]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.89 [1.18 ; 3.04 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 13 0% 7,546 moderate low Dizziness TRAE (grade 3-4)detailed results KEYNOTE-021, 2016 1.05 [0.02; 53.86]
1.05 [0.02 ; 53.86 ] KEYNOTE-021, 2016 1 0% 121 NA not evaluable Dysgeusia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
1.00 [0.10 ; 9.69 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016 3 0% 955 moderate not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.20 [0.06; 0.71]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 2.18 [0.65; 7.39]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 2.00 [0.60; 6.70]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.29 [0.03; 2.62]
CheckMate 9LA, 2021 3.97 [0.84; 18.81]
IMpower-131 (ACnP), 2020 1.89 [0.75; 4.80]
KEYNOTE-021, 2016 4.32 [0.19; 97.73]
KEYNOTE-024 (PDL1>50%), 2016 0.38 [0.07; 2.00]
KEYNOTE-042 (PDL1>1%), 2019 0.36 [0.09; 1.36]
MYSTIC (D ; all population), 2020 0.81 [0.27; 2.45]
MYSTIC (DT ; all population), 2020 1.09 [0.39; 3.03]
0.98 [0.56 ; 1.74 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 11 49% 6,452 moderate low Febrile neutropenia TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 1.38 [0.60; 3.15]
IMpower-131 (ACnP), 2020 2.66 [1.10; 6.46]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
1.88 [1.04 ; 3.41 ] CheckMate 9LA, 2021, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016 3 0% 1,496 moderate not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 1.19 [0.36; 3.94]
1.19 [0.36 ; 3.94 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
1.00 [0.02 ; 50.55 ] IMpower-131 (ACnP), 2020 1 0% 668 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 11.47 [1.48; 88.87]
IMpower-131 (ACnP), 2020 1.00 [0.06; 16.05]
KEYNOTE-042 (PDL1>1%), 2019 13.68 [0.77; 241.54]
KEYNOTE-189, 2018 4.02 [0.21; 76.41]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
MYSTIC (DT ; all population), 2020 13.52 [0.76; 239.13]
5.23 [1.82 ; 15.02 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 7 0% 5,216 moderate not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
IMpower-131 (ACnP), 2020 2.00 [0.07; 59.91]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 1.90 [0.06; 56.82]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.11 [0.34 ; 3.61 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 10 0% 6,038 moderate critical Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-042 (PDL1>1%), 2019 5.82 [0.29; 116.52]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 1.90 [0.06; 56.82]
1.88 [0.40 ; 8.89 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 5 0% 3,606 moderate serious Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.18 [0.02; 59.79]
CheckMate 9LA, 2021 1.95 [0.07; 58.39]
EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
IMpower-131 (ACnP), 2020 4.02 [0.18; 89.44]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
KEYNOTE-189, 2018 2.00 [0.09; 44.56]
MYSTIC (D ; all population), 2020 3.83 [0.17; 85.25]
MYSTIC (DT ; all population), 2020 5.73 [0.29; 114.82]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.81 [0.68 ; 4.80 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 13 0% 7,569 moderate critical Increase AST TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 3.87 [0.17; 86.12]
KEYNOTE-021, 2016 1.05 [0.06; 17.21]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.35; 10.63]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.67 [0.48 ; 5.82 ] EMPOWER lung1 (all population), 2021, KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 2019, ORIENT-11, 2020 4 0% 2,466 moderate not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 3.51 [0.72; 17.07]
CheckMate 9LA, 2021 2.46 [0.47; 12.75]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
KEYNOTE-021, 2016 1.05 [0.06; 17.21]
KEYNOTE-042 (PDL1>1%), 2019 1.75 [0.58; 5.26]
ORIENT-11, 2020 0.49 [0.01; 24.91]
2.02 [0.97 ; 4.18 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 2019, ORIENT-11, 2020 6 0% 3,703 moderate not evaluable Increased lacrimation (TRAE grade 3-4)detailed results KEYNOTE-021, 2016 1.05 [0.02; 53.86]
1.05 [0.02 ; 53.86 ] KEYNOTE-021, 2016 1 0% 121 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 7.55 [2.24; 25.47]
7.55 [2.24 ; 25.47 ] CheckMate 9LA, 2021 1 0% 707 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 0.16 [0.02; 1.33]
KEYNOTE-189, 2018 1.00 [0.03; 29.86]
0.55 [0.15 ; 2.03 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018 6 0% 3,500 moderate serious Leucopenia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.05 [0.00; 0.92]
IMpower-131 (ACnP), 2020 1.46 [0.72; 2.93]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
KEYNOTE-042 (PDL1>1%), 2019 0.05 [0.00; 0.82]
0.35 [0.04 ; 2.78 ] CheckMate 026 (PDL1>1%), 2016, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 2019 4 69% 2,570 moderate not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09]
CheckMate 9LA, 2021 4.93 [0.57; 42.41]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
3.26 [0.66 ; 16.22 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021 3 0% 1,934 moderate not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
0.98 [0.02 ; 49.83 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Myalgia TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
1.46 [0.11 ; 19.02 ] IMpower-131 (ACnP), 2020, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,919 moderate not evaluable Myocarditis TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
1.94 [0.06 ; 57.80 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Myositis TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
0.79 [0.08 ; 7.57 ] IMpower-131 (ACnP), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-189, 2018 3 0% 1,579 moderate not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.19 [0.02; 1.67]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.85 [0.22; 3.21]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.28 [0.06; 1.35]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.18 [0.16; 8.49]
CheckMate 9LA, 2021 1.63 [0.39; 6.89]
IMpower-131 (ACnP), 2020 3.55 [0.73; 17.23]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
KEYNOTE-024 (PDL1>50%), 2016 0.16 [0.01; 3.21]
KEYNOTE-042 (PDL1>1%), 2019 0.07 [0.00; 1.21]
MYSTIC (D ; all population), 2020 0.08 [0.00; 1.41]
MYSTIC (DT ; all population), 2020 0.16 [0.02; 1.30]
0.55 [0.25 ; 1.19 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 11 39% 6,452 moderate critical Nephritis TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
KEYNOTE-189, 2018 6.06 [0.34; 109.04]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
1.79 [0.47 ; 6.87 ] EMPOWER lung1 (all population), 2021, IMpower-131 (ACnP), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 7 0% 4,971 moderate serious Neutropenia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.02 [0.00; 0.25]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.19 [0.63; 2.24]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.01 [0.00; 0.23]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.03 [0.00; 0.46]
CheckMate 9LA, 2021 0.71 [0.41; 1.24]
IMpower-131 (ACnP), 2020 0.93 [0.65; 1.35]
KEYNOTE-021, 2016 2.14 [0.19; 24.25]
KEYNOTE-024 (PDL1>50%), 2016 0.02 [0.00; 0.35]
KEYNOTE-042 (PDL1>1%), 2019 0.02 [0.00; 0.14]
MYSTIC (D ; all population), 2020 0.02 [0.00; 0.18]
MYSTIC (DT ; all population), 2020 0.01 [0.00; 0.20]
0.14 [0.06 ; 0.36 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 11 84% 6,452 moderate critical Pancreatitis TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 2.00 [0.07; 59.91]
KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
KEYNOTE-189, 2018 2.00 [0.09; 44.56]
1.73 [0.31 ; 9.58 ] IMpower-131 (ACnP), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018 4 0% 2,830 moderate not evaluable Pancytopenia TRAE (grade 3-4)detailed results KEYNOTE-021, 2016 0.52 [0.02; 15.84]
0.52 [0.02 ; 15.84 ] KEYNOTE-021, 2016 1 0% 121 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
IMpower-131 (ACnP), 2020 2.01 [0.37; 11.06]
KEYNOTE-042 (PDL1>1%), 2019 0.10 [0.01; 1.76]
0.98 [0.25 ; 3.89 ] CheckMate 026 (PDL1>1%), 2016, EMPOWER lung1 (all population), 2021, IMpower-131 (ACnP), 2020, KEYNOTE-042 (PDL1>1%), 2019 4 9% 3,146 moderate not evaluable Peripheral oedema TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
1.02 [0.06 ; 16.38 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-021, 2016 2 0% 651 moderate not evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 4.04 [0.45; 36.31]
KEYNOTE-042 (PDL1>1%), 2019 0.08 [0.00; 1.43]
0.64 [0.01 ; 29.61 ] IMpower-131 (ACnP), 2020, KEYNOTE-042 (PDL1>1%), 2019 2 78% 1,919 moderate not evaluable Pneumonia TRAE (grade 3-4)detailed results KEYNOTE-021, 2016 2.12 [0.07; 64.42]
2.12 [0.07 ; 64.42 ] KEYNOTE-021, 2016 1 0% 121 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
IMpower-131 (ACnP), 2020 1.68 [0.40; 7.07]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
KEYNOTE-024 (PDL1>50%), 2016 3.97 [0.44; 35.97]
KEYNOTE-042 (PDL1>1%), 2019 20.97 [2.81; 156.36]
KEYNOTE-189, 2018 1.00 [0.30; 3.35]
MYSTIC (D ; all population), 2020 3.85 [0.43; 34.59]
MYSTIC (DT ; all population), 2020 7.74 [0.96; 62.17]
ORIENT-11, 2020 0.98 [0.09; 10.96]
2.50 [1.33 ; 4.70 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 10 0% 6,038 moderate low Pruritus TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.06 [0.02; 53.93]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 3.97 [0.18; 88.42]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 4.77 [0.21; 106.62]
CheckMate 9LA, 2021 5.89 [0.29; 118.02]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-042 (PDL1>1%), 2019 3.88 [0.17; 86.15]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.90 [0.64 ; 5.69 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 10 0% 5,877 moderate critical Pyrexia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
0.66 [0.05 ; 8.61 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016 2 0% 834 moderate not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.98 [0.18; 21.94]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 2.13 [0.07; 64.04]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 18.21 [1.05; 315.26]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 7.20 [0.36; 145.12]
CheckMate 9LA, 2021 11.88 [0.66; 213.53]
EMPOWER lung1 (all population), 2021 3.87 [0.17; 86.12]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.38 [0.23; 8.34]
IMpower-131 (ACnP), 2020 2.01 [0.18; 22.23]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
KEYNOTE-042 (PDL1>1%), 2019 5.82 [0.29; 116.52]
MYSTIC (D ; all population), 2020 2.88 [0.30; 27.79]
MYSTIC (DT ; all population), 2020 0.95 [0.06; 15.23]
ORIENT-11, 2020 0.16 [0.02; 1.56]
2.22 [1.08 ; 4.57 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 13 0% 7,791 moderate low Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09]
1.97 [0.07 ; 59.09 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 12.07 [0.67; 217.19]
12.07 [0.67 ; 217.19 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Sepsis TRAE (grade 3-4)detailed results KEYNOTE-021, 2016 2.12 [0.07; 64.42]
2.12 [0.07 ; 64.42 ] KEYNOTE-021, 2016 1 0% 121 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
KEYNOTE-021, 2016 1.05 [0.06; 17.21]
KEYNOTE-024 (PDL1>50%), 2016 12.12 [0.67; 218.98]
KEYNOTE-042 (PDL1>1%), 2019 10.81 [1.39; 83.96]
KEYNOTE-189, 2018 1.00 [0.30; 3.35]
2.45 [0.73 ; 8.21 ] IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018 5 30% 2,951 moderate not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 5.00 [0.58; 43.09]
5.00 [0.58 ; 43.09 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72]
KEYNOTE-021, 2016 0.52 [0.02; 15.84]
KEYNOTE-024 (PDL1>50%), 2016 0.24 [0.01; 5.39]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
0.46 [0.08 ; 2.53 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 4 0% 2,206 moderate not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.04 [0.01; 0.31]
CheckMate 9LA, 2021 1.09 [0.44; 2.70]
IMpower-131 (ACnP), 2020 1.16 [0.68; 2.00]
KEYNOTE-021, 2016 1.05 [0.14; 7.73]
KEYNOTE-024 (PDL1>50%), 2016 0.06 [0.00; 1.02]
KEYNOTE-042 (PDL1>1%), 2019 0.10 [0.01; 0.75]
MYSTIC (D ; all population), 2020 0.03 [0.00; 0.42]
MYSTIC (DT ; all population), 2020 0.03 [0.00; 0.42]
0.21 [0.07 ; 0.67 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 8 76% 5,025 moderate serious Thyroiditis TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
0.78 [0.08 ; 7.49 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018 3 0% 2,162 moderate not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.10 [0.01; 1.78]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.43 [0.32; 6.48]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.10 [0.01; 0.76]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.19 [0.02; 1.60]
CheckMate 9LA, 2021 1.17 [0.35; 3.88]
IMpower-131 (ACnP), 2020 3.02 [0.31; 29.16]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.06; 15.71]
KEYNOTE-042 (PDL1>1%), 2019 0.24 [0.01; 5.36]
MYSTIC (D ; all population), 2020 0.07 [0.00; 1.18]
MYSTIC (DT ; all population), 2020 0.07 [0.00; 1.18]
0.46 [0.20 ; 1.06 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 11 35% 6,452 moderate low hepatitis (Autoimmune) AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
KEYNOTE-407, 2018 10.24 [0.56; 188.30]
5.05 [0.55 ; 46.09 ] EMPOWER lung1 (all population), 2021, KEYNOTE-407, 2018 2 0% 1,255 low not evaluable Acute kidney injury AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.24 [0.01; 5.34]
0.24 [0.01 ; 5.34 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Alopecia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.24 [0.01; 5.34]
KEYNOTE-407, 2018 0.33 [0.03; 3.22]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.42 [0.09 ; 1.95 ] EMPOWER lung1 (all population), 2021, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 4 0% 2,699 moderate not evaluable Anaemia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.03 [0.01; 0.13]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.08 [0.03; 0.20]
KEYNOTE-189, 2018 1.07 [0.67; 1.71]
KEYNOTE-407, 2018 0.72 [0.46; 1.11]
MYSTIC (D ; all population), 2020 0.16 [0.07; 0.34]
MYSTIC (DT ; all population), 2020 0.12 [0.05; 0.28]
0.20 [0.08 ; 0.55 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 92% 3,855 moderate serious Arthralgia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
KEYNOTE-407, 2018 2.03 [0.37; 11.17]
1.52 [0.33 ; 6.97 ] EMPOWER lung1 (all population), 2021, KEYNOTE-407, 2018 2 0% 1,255 low not evaluable Asthenia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.36 [0.07; 1.89]
KEYNOTE-189, 2018 1.83 [0.78; 4.31]
KEYNOTE-407, 2018 0.60 [0.21; 1.66]
MYSTIC (D ; all population), 2020 0.95 [0.41; 2.23]
MYSTIC (DT ; all population), 2020 0.86 [0.36; 2.05]
0.93 [0.61 ; 1.43 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 0% 3,855 moderate not evaluable Back pain AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
MYSTIC (D ; all population), 2020 0.32 [0.03; 3.05]
MYSTIC (DT ; all population), 2020 0.63 [0.10; 3.80]
0.48 [0.13 ; 1.77 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 0% 2,141 moderate not evaluable Blood creatinine increased AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
0.48 [0.02 ; 14.38 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Colitis AE (grade 3-4)detailed results KEYNOTE-407, 2018 2.04 [0.50; 8.23]
2.04 [0.50 ; 8.23 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Constipation AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.38 [0.23; 8.34]
KEYNOTE-189, 2018 2.00 [0.22; 18.06]
KEYNOTE-407, 2018 0.67 [0.11; 4.04]
MYSTIC (D ; all population), 2020 0.95 [0.06; 15.31]
MYSTIC (DT ; all population), 2020 1.90 [0.17; 21.07]
1.21 [0.48 ; 3.01 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 0% 3,855 moderate not evaluable Cough AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.84 [0.06; 55.14]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
KEYNOTE-407, 2018 0.67 [0.11; 4.04]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.90 [0.25 ; 3.23 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 5 0% 3,158 low not evaluable Decreased appetite AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.06; 15.46]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
KEYNOTE-189, 2018 3.02 [0.36; 25.28]
KEYNOTE-407, 2018 1.21 [0.37; 4.02]
MYSTIC (D ; all population), 2020 1.44 [0.40; 5.14]
MYSTIC (DT ; all population), 2020 1.43 [0.40; 5.11]
1.49 [0.78 ; 2.85 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 0% 3,855 moderate not evaluable Diarrhoea AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.16 [0.02; 1.32]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.23 [0.01; 5.09]
KEYNOTE-189, 2018 1.79 [0.71; 4.50]
KEYNOTE-407, 2018 1.88 [0.69; 5.16]
MYSTIC (D ; all population), 2020 0.38 [0.07; 1.96]
MYSTIC (DT ; all population), 2020 2.12 [0.73; 6.17]
1.08 [0.51 ; 2.29 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 44% 3,855 moderate serious Dyspnoea AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.17; 21.41]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
KEYNOTE-189, 2018 0.67 [0.30; 1.48]
KEYNOTE-407, 2018 3.04 [0.31; 29.44]
MYSTIC (D ; all population), 2020 1.61 [0.58; 4.47]
MYSTIC (DT ; all population), 2020 1.11 [0.37; 3.33]
1.10 [0.66 ; 1.84 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 0% 3,855 moderate serious Epistaxis AE (grade 3-4)detailed results KEYNOTE-407, 2018 1.01 [0.02; 50.94]
1.01 [0.02 ; 50.94 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Fatigue AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.72 [0.16; 3.24]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.30 [0.06; 1.51]
KEYNOTE-189, 2018 2.37 [0.89; 6.34]
KEYNOTE-407, 2018 0.82 [0.33; 2.01]
MYSTIC (D ; all population), 2020 1.20 [0.47; 3.07]
MYSTIC (DT ; all population), 2020 1.31 [0.52; 3.31]
1.10 [0.69 ; 1.75 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 13% 3,855 moderate not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-28 21:59 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 196,36,228,174,171,173,307,165,163,176,308,164,166,220
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,746,745,856,634,861,416,864,769,980,369,743